LogicBio Therapeutics Inc (NASDAQ:LOGC) – Stock analysts at William Blair raised their Q2 2019 earnings estimates for shares of LogicBio Therapeutics in a research note issued on Tuesday, May 14th. William Blair analyst R. Prasad now expects that the company will earn ($0.43) per share for the quarter, up from their prior estimate of ($0.50). William Blair also issued estimates for LogicBio Therapeutics’ Q3 2019 earnings at ($0.43) EPS, Q4 2019 earnings at ($0.48) EPS, FY2019 earnings at ($1.69) EPS and FY2020 earnings at ($2.44) EPS.

LogicBio Therapeutics (NASDAQ:LOGC) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.02).

Other research analysts have also issued research reports about the stock. Roth Capital assumed coverage on shares of LogicBio Therapeutics in a research note on Wednesday, May 1st. They set a “buy” rating and a $26.00 price target on the stock. Zacks Investment Research lowered shares of LogicBio Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. LogicBio Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $24.00.

Shares of LogicBio Therapeutics stock opened at $14.54 on Thursday. LogicBio Therapeutics has a 12-month low of $6.70 and a 12-month high of $18.00. The company has a market cap of $326.71 million and a price-to-earnings ratio of -4.78.

A number of institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. acquired a new position in LogicBio Therapeutics during the 4th quarter valued at approximately $31,000. Northern Trust Corp increased its stake in LogicBio Therapeutics by 4.7% during the 1st quarter. Northern Trust Corp now owns 87,951 shares of the company’s stock valued at $869,000 after purchasing an additional 3,982 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in LogicBio Therapeutics by 26.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 20,515 shares of the company’s stock valued at $203,000 after purchasing an additional 4,315 shares in the last quarter. American International Group Inc. acquired a new position in LogicBio Therapeutics during the 4th quarter valued at approximately $56,000. Finally, New York State Common Retirement Fund acquired a new position in LogicBio Therapeutics during the 1st quarter valued at approximately $57,000. Institutional investors and hedge funds own 54.48% of the company’s stock.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.

Read More: Why is the ex-dividend date different from the record date?

Earnings History and Estimates for LogicBio Therapeutics (NASDAQ:LOGC)

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.